TRCT
APGE

Tower Research Capital (TRC)’s Apogee Therapeutics APGE Stock Holding History

Tower Research Capital (TRC)’s Portfolio APGE Stock Details APGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$226K Sell
1,701
-4,489
-73% -$404K 0.01% 1597
2026
Q1 		$521K Buy
6,190
+2,520
+69% +$183K 0.01% 884
2025
Q4 		$277K Buy
3,670
+706
+24% +$44.5K 0.01% 1208
2025
Q3 		$118K Sell
2,964
-5,455
-65% -$208K ﹤0.01% 1872
2025
Q2 		$366K Buy
8,419
+7,434
+755% +$283K 0.01% 1247
2025
Q1 		$36.8K Sell
985
-5,302
-84% -$205K ﹤0.01% 2453
2024
Q4 		$285K Buy
6,287
+4,910
+357% +$250K 0.01% 1447
2024
Q3 		$80.9K Sell
1,377
-4,654
-77% -$223K ﹤0.01% 2392
2024
Q2 		$237K Buy
6,031
+5,775
+2,256% +$280K ﹤0.01% 1933
2024
Q1 		$17K Sell
256
-7,570
-97% -$331K ﹤0.01% 3142
2023
Q4 		$219K Buy
7,826
+7,361
+1,583% +$148K ﹤0.01% 2028
2023
Q3 		$9.9K Buy
+465
New +$10.2K ﹤0.01% 4168

Other funds holding APGE

VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

Tower Research Capital (TRC)'s APGE Position: Q2 2026 in Review

Tower Research Capital (TRC) reduced its Apogee Therapeutics (APGE) stake by 73% in Q2 2026, selling an estimated $404K and leaving 1,701 shares worth $226K. The position accounts for 0.01% of the portfolio, ranked #1597.

Tower Research Capital (TRC) first reported a position in APGE in Q3 2023 and has held it in 12 quarters since. The position peaked at $521K in Q1 2026. 289 funds tracked by Wall St. Rank hold APGE as of Q2 2026.

  • Tower Research Capital (TRC) held 1,701 shares of Apogee Therapeutics worth $226K as of Q2 2026.
  • Tower Research Capital (TRC) sold 4,489 Apogee Therapeutics shares in Q2 2026, an estimated $404K.
  • Apogee Therapeutics made up 0.01% of Tower Research Capital (TRC)'s portfolio in Q2 2026, its #1597 holding.
  • Tower Research Capital (TRC) first reported a position in Apogee Therapeutics in Q3 2023 and has held it in 12 quarters since.
  • Tower Research Capital (TRC)'s Apogee Therapeutics position peaked at $521K in Q1 2026.
  • 289 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q2 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.